29 Sep 2022
Coverage1 for all routine childhood vaccinations2 administered to children under five in England in 2021-22 has been published today.
NHS Digital’s Childhood Vaccination Coverage Statistics contains information on the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of vaccination evaluated rapidly (COVER) programme.
This report, which is co-authored with the UK Health Security Agency (UKHSA), includes information on 14 measures3 of vaccination coverage. At a national level, coverage has decreased for 13 of these.
The only vaccination where coverage has increased is Pneumococcal Disease (PCV) primary, but this is a comparison with 2019-20’s figures, as 2020-21 data is not available.
Disruption caused by the COVID-19 pandemic, beginning in March 2020, is likely to have caused some of the decreases in vaccine coverage seen in 2020-21 and 2021-22, compared to earlier years.4
Chris Roebuck, NHS Digital’s Chief Statistician, said: “We publish these statistics to help inform the development and evaluation of government policy on immunisation.
“The annual report is also used to assess the effectiveness of the vaccine programme at a local, regional and national level.”
Measles, Mumps and Rubella (MMR) vaccine
In 2021-22, 89.2% of children at 24 months had completed their first dose of the MMR vaccine, which is a decrease from 90.3% in 2020-21. The World Health Organization (WHO) target is 95%.
Regional data5 shows seven of the nine regions reached 90% coverage. No region exceeded the 95% target. The North East had the highest level of coverage at 94.5% (down from 95.3% the previous year). London had the lowest level of coverage in 2021-22 at 79.9% (down from 82.4% in 2020-21).
In 2021-22, 16 local authorities out of 149 had coverage levels of 95% and above. Coverage of less than 90% was reported for 61 local authorities including all London authorities.
In 2021-22, 85.7% of children received their 2nd dose of MMR vaccine (MMR2) by their 5th birthday, a decrease from 86.6% in the previous year.
6-in-1 and 5-in-1 vaccines6
Coverage for the 6-in-1/5-in-1 vaccine, which protects against diphtheria, pertussis, tetanus, polio, disease caused by Haemophilus influenzae type b and hepatitis B, decreased among children aged 12 months, 24 months and five years.
In 2021-22, 91.8% of children were reported to have completed their primary course of 3 doses of the 6-in-1 at 12 months. This is a decrease from 2020-21 when coverage was 92.0%.
In 2021-22, 8 out of 9 regions reached 90% coverage for the 6-in-1 vaccine. The North East was the only region to exceed the national target of 95% and London had the lowest coverage at 86.5%.
Among children aged 24 months, coverage of the 6-in-1 vaccine fell from 93.8% in 2020-21 to 93.0% in 2021-22.
For children aged five years, coverage for the 5-in-1 vaccine was 94.4% in 2021-22. This is lower than the 95.2% coverage reported in 2020-21.
Other vaccinations
The report also includes coverage data for the pneumococcal disease (PCV), rotavirus, meningococcal group B (MenB)7, Hib booster and meningococcal group C vaccine (Hib/MenC) and children’s flu vaccines.
List of vaccinations, ages at which coverage is measured and coverage for past three years:
Vaccination |
Age administered |
Age measured |
2021-22 |
2020-21 |
2019-20 |
Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (DTaP/IPV/Hib)* |
8, 12 & 16 weeks |
12 months |
91.8 |
92.0 |
92.6 |
24 months |
93.0 |
93.8 |
93.8 |
||
5 years |
94.4 |
95.2 |
95.2 |
||
Pneumococcal disease (PCV)** |
12 weeks |
12 months |
93.8 |
n/a |
93.2 |
Rotavirus |
8 & 12 weeks |
12 months |
89.9 |
90.2 |
90.1 |
Meningococcal group B (MenB) |
8 & 16 weeks |
12 months |
91.5 |
92.1 |
92.5 |
Haemophilus influenzae type b and meningococcal group C (Hib / MenC) |
1 year |
24 months |
89.0 |
90.2 |
90.5 |
5 years |
91.7 |
92.3 |
92.5 |
||
Measles/mumps/rubella (MMR) |
1 year |
24 months |
89.2 |
90.3 |
90.6 |
5 years |
93.4 |
94.3 |
94.5 |
||
Pneumococcal disease (PCV) booster |
1 year |
24 months |
89.3 |
90.1 |
90.4 |
Meningococcal group B (MenB) booster |
1 year |
24 months |
88.0 |
89.0 |
88.7 |
Diphtheria, tetanus, pertussis, and polio (DTaP/IPV) booster |
3 yrs 4 months to 5 yrs |
5 years |
84.2 |
85.3 |
85.4 |
Measles/mumps/rubella (MMR) second dose |
3 yrs 4 months to 5 yrs |
5 years |
85.7 |
86.6 |
86.8 |
* From 2019-20, for the 12-month cohort, coverage is evaluated against the 6-in-1 hexavalent vaccine.
From 2020-21, for the 24-month cohort, coverage is evaluated against the 6-in-1 hexavalent vaccine. Other measures reflect coverage for the 5-in-1 pentavalent vaccine (DTAP/IPV/Hib).
** Since January 2020, PCV primary course (at 12 months) changed to a single vaccination at age 12 weeks. Prior to that it was 2 doses at ages 8 and 16 weeks.
Read the full report
Childhood Vaccination Coverage Statistics
ENDS
NHS England Media Team
0300 303 3888
media@nhsdigital.nhs.net
For media enquiries please email nhsengland.media@nhs.net or call 0300 30 33 888.